USPTO serial 79395459
ALTAVOL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 29, 2025
- Examiner
- DUBIN, DAVID I
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ALTAVOL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of dermatological diseases; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in the treatment of hematology diseases; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in the treatment of ophthalmology diseases; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma | ACTIVE | — |
| 010 | [ Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; ] Medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for the diagnosis and treatment of gastro-intestinal diseases; medical apparatus and instruments for the diagnosis, prevention, and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; medical apparatus and instruments for the diagnosis, prevention, and treatment of hematology diseases and disorders; medical apparatus and instruments for use in tissue and organ transplantation surgery; medical apparatus and instruments for the diagnosis, prevention, and treatment of eye diseases and eye conditions; [ medical apparatus and instruments for the diagnosis, prevention, and treatment of heart rhythm disorders; ] medical apparatus and instruments for the diagnosis, prevention, and treatment of immune system diseases and disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of kidney diseases; [ medical apparatus and instruments for the diagnosis, prevention, and treatment of diabetes; medical apparatus and instruments for the diagnosis, prevention, and treatment of hypertension; ] medical apparatus and instruments for the diagnosis, prevention, and treatment of skin disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of urinary diseases and disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of ophthalmological diseases and disorders; medical apparatus and instruments for the diagnosis, prevention, and treatment of cancer and tumors; medical apparatus and instruments for the diagnosis, prevention, and treatment of allergies; medical apparatus and instruments for the diagnosis, prevention, and treatment of bone diseases; medical apparatus and instruments for the diagnosis, prevention, and treatment of respiratory diseases and asthma; radiological apparatus for medical purposes and instruments being radiological apparatus for medical purposes; genetic testing apparatus for medical purposes and instruments being genetic testing apparatus for medical purposes; electromagnetic drug delivery apparatus for medical use and instruments being electromagnetic drug delivery apparatus for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments being medical diagnostic apparatus for testing DNA and RNA samples for medical use; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and instruments being medical apparatus for introducing pharmaceutical preparations into the human body | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 25, 2026 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 10, 2026 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Mar 12, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 19, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 19, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 19, 2026 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Dec 2, 2025 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Nov 10, 2025 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Nov 3, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 29, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 24, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 8, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 8, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 20, 2025 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Jul 29, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 29, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 9, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jun 13, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 15, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Apr 29, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 29, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 23, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 1, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 31, 2025 | LOPR | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | — |
| Mar 31, 2025 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Feb 10, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 10, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 10, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 17, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 2, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 2, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 17, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 16, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 29, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 29, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 29, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 29, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 29, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 21, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 21, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 15, 2024 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| May 10, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |